Development of New Regimens for Tuberculosis Zhenkun Ma, Ph.D.
|
|
- Emily Price
- 5 years ago
- Views:
Transcription
1 Development of New Regimens for Tuberculosis Chief Scientific Officer Global Alliance for TB Drug Development 40 Wall Street, 24th Floor New York, NY USA 1 Outline What are the unmet needs in TB therapy? What are the approaches in TB drug development? How to identify novel TB regimens Summary 2 Part 1: What are the unmet needs in TB therapy? 3 1
2 TB is a global disease 12 million active TB cases; 650,000 are multidrug-resistant TB (MDR-TB) 98% of TB deaths occur in the developing world India and China have the highest TB and MDR-TB burdens Africa has the highest rates of infection, HIV/TB co-infection, and death Highest rates of MDR-TB and extensively drug-resistant TB (XDR-TB) are in Europe 4 TB is a multidimensional problem Drug Sensitivity Drug-sensitive TB (DS-TB) Latent TB Stage of Infection Drug-resistant TB (DR-TB) Active TB HIV- HIV+ HIV Status 5 Current TB therapies active TB Drug-sensitive TB (DS-TB) 2HRZE/4RH; or 2HRZE/4HRE in settings with high isoniazid resistance TB therapy, plus antiretroviral therapy (ART); drug-drug interactions (DDI) Drug-resistant TB (DR-TB) >18 months empirical MDR-TB regimen or drug sensitivity test (DST) guided individualized therapy MDR-TB therapy, plus ART; 6-10 daily medications for >18 months, high levels of toxicity and drug-drug interactions HIV- HIV+ 6 H = Isoniazid, R = Rifampicin, Z = Pyrazinamide, E = Ethambutol 2
3 Current TB therapies latent TB Drug-sensitive TB (DS-TB) 9 months, daily or twice weekly of H; 4 months, daily of R; or 3 months, once weekly of HP 9 months, daily or twice weekly of H; or 3 months, once weekly of HP for patients not taking ART Drug-resistant TB (DR-TB) Lack of appropriate diagnostics and treatment Lack of appropriate diagnostics; close contacts to DR-TB cases should be treated with >2 drugs to which the source isolate is susceptible HIV- HIV+ 7 H = Isoniazid, R = Rifampicin, P = Rifapentine Complicated, individualized therapies are needed based on DST and HIV statuses; difficult to implement, particularly in developing world Improper treatments are common due to lack of affordable and reliable diagnostics and rapid DST DS-TB treatment is lengthy (6-9 months), complicated, and challenged by the development of drug resistance DR-TB (MDR- and XDR-TB) treatment is lengthy (>18 months), toxic, inconvenient (including injectables), and expensive Treatment of TB/HIV co-infected patients is complicated with high pill burden and toxicity; complicated by drug-drug interactions Shorter, simpler and universal therapies (active against both DS- and DR- TB and free of DDI) that are less dependent on DST are highly desirable 8 Unmet needs in TB therapy Desired regimen profiles Shorter duration: Active against drug persistence populations Active against both DS- and DR-TB: Novel mechanism of action Co-administration with ART: Low potential for drug-drug interactions Convenient: Orally bioavailable, once daily or less frequent dosing Safe: Good safety and tolerability profile Affordable: Low cost of goods 9 3
4 Part 2: What are the approaches in TB drug development? 10 Process for TB drug development Drug Discovery Preclinical Development Clinical Development Discovery Pre-clinical Phase I Phase II Phase III Single Drug Drug Combination 11 Late-stage development (after human proof-of-concept) needs to be conducted in combination with other TB drugs to prevent the development of drug resistance Conventional approach 1 Replacing an existing drug (D) with a new drug (X) from current regimen (DS-TB) X D ABCD ABCX Examples: 2RHZE/4RH 2RHZM/2RHM (REMoxTB trial) 2RHZE/4RH 2RMZE/2RM (REMoxTB trial) 2RHZE/4RH 2RHZG/2RHG (OFLUTOB trial) M = Moxifloxacin G = Gatifloxacin 12 For REMox, see For OFLUTOB, see 4
5 Conventional approach 2 Adding a new drug (X) to current regimen (MDR-TB) EFGH X EFGHX Examples: BR BR+J (Bedaquiline trial) OBR OBR+O (Delamanid trial) BR = Background Regimen, OBR = Optimized Background Regimen J = TMC207 (Bedaquiline), O = OPC67683 (Delamanid) 13 For TMC207, see For OPC67683, see 14 Conventional approach: issues DS-TB: limited improvement over current regimens (e.g., REMoxTB and OFLUTOB trials) Potential for shortening therapy from 6 to 4 months Drug resistance Drug-drug interaction DR-TB: limited improvement; difficult to implement (e.g., Bedaquiline and Delamanid MDR-TB trials) Improvement in efficacy over current regimens More complicated treatment More expensive New approach Replacing entire regimen with a novel regimen XYZ ABCD ABCD XYZ Examples: 2RHZE/4RH 4PaMZ (NC-001 and NC-002) Pa = PA-824, M = Moxifloxacin, Z = Pyrazinamide 15 For NC-002, see 5
6 16 Process for novel regimen development Drug discovery Compound class 1 Compound class 2 Compound class 3 Compound class 4 Compound class 5 Candidate selection Drugs to regimens Single compound preclinical development Phase I EBA Available Drug Candidate Pool Regimen Mouse model combo EBA Regimen development Phase IIb Phase III Regimen selection Regimen A Regimen B Regimen C Advantages: dramatic improvement over current therapies, addresses the majority of unmet needs Potential to treat both DS- and DR-TB Dramatically shortens duration of therapy Potential to address DDI with ART Challenges: a higher risk approach to studying multiple new drugs in the same regimen Scientific challenges Regulatory issues Intellectual property issues in working with multiple sponsors 17 New approach: advantages and challenges Part 3: How to identify novel TB regimens 18 6
7 Drug classes available for regimen development Orally active compounds with human PoC: Known class (Pre-existing drug-r) Rifampicin/Rifapentine Isoniazid Pyrazinamide Ethambutol Moxifloxacin/Gatifloxacin Novel class (No pre-existing drug-r) Clofazimine Linezolid/PNU Bedaquiline PA-824/Delamanid SQ A total of 330 potential 3- and 4-drug combinations based on 10 classes of compounds (one member from each class with a single dose) The need for prioritization using preclinical models Drug to regimen An unbiased, data-driven approach: Clinical studies 20 Preclinical Dev Phase I (SAD) Single dose PK/safety Combo (Mouse Acute Model) Bactericidal Activity: Initial Screening Combo (Mouse Relapse Model) Sterilizing Activity: Duration of Therapy Phase I (MAD) Multiple dose PK/safety PK Interaction Confirmation of Efficacy Secondary Infection Model Preclinical studies Phase II (Single EBA) Human PoC (single drug) Combo Safety Combination Specific Safety Human PoC (regime) Phase II (Combo EBA) Mouse infection model M. Tuberculosis aerosol infection Rx start Measuring CFU in lung Day -14 Day 0 M1 M2 M3 M4 M5 (15) (15) (15) (15) 15 mice held for 3 months without treatment and then sacrificed to determine permanent cure without relapse 21 7
8 PaMZ bactericidal activity in mouse model Lung CFU R = Rifampicin H = Isoniazid Z = Pyrazinamide Pa = PA-824 M = Moxifloxacin 22 Week Eric Nuermberger, et al., Antimicrob Agents Chemother April; 52(4): PaMZ sterilizing activity in mouse model Treatment a Proportion (%) of mice cured after treatment for: 4 mos 5 mos 6 mos 2RHZ/4RH 10/20 (50) 20/20 (100) 20/20 (100) 2PaMZ/4PaM 20/20 (100) b 20/20 (100) 20/20 (100) a Drug doses (mg/kg): R, 10; H, 25; Z, 150; M, 100; and Pa, 100; All drugs were given orally 5 days a week b P < 0.01 versus regimen 1 23 Eric Nuermberger, et al., Antimicrob Agents Chemother April; 52(4): PaMZ combination EBA design (NC-001) Study Arms PaMZ Pa: PA-824 M: Moxifloxacin Z: Pyrazinamide PaZ (M pbo) Rx for 2 Weeks RHZE Visits Day Pre-treatment Treatment Follow Up 24 Andreas H Diacon, et al. Lancet, 2012; 380 (9846):
9 PaMZ combination EBA results (NC-001) Bi-linear regression: LogCFU changes from baseline 25 Andreas H Diacon, et al. Lancet, 2012; 380 (9846): Current TB therapies are lengthy, complicated and challenged by drug resistance and drug-drug interaction problems; difficult to implement, particularly in developing world Shorter, simpler and totally oral therapies that are active against both DS- and DR-TB, less dependent on DST and free of DDI are highly desirable Conventional approaches in TB drug development by replacing or adding a new drug into current regimens provide limited improvement over current therapies A new approach that focuses on novel regimen development by replacing all or most drugs from the current regimens with new drugs can bring dramatic improvement over current therapies 26 Summary Thank you! 27 9
10 28 10
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationSirturo: a new treatment against multidrug resistant tuberculosis
Sirturo: a new treatment against multidrug resistant tuberculosis TB is an on-going problem WHO estimated incidence of new TB cases 2009 Global Tuberculosis Control: WHO report 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html
More informationThe innovation gaps and challenges for MDR-TB. Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board
The innovation gaps and challenges for the diagnostic and treatment of TB and MDR-TB Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board Diagnosis Overview of
More informationMultiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
More informationShorter TB regimens What is in de pipeline? Martin Boeree, Associate Professor Radboudumc, Nijmegen, the Netherlands Tuesday, 23 September, 2014
Shorter TB regimens What is in de pipeline? Martin Boeree, Associate Professor Radboudumc, Nijmegen, the Netherlands Tuesday, 23 September, 2014 Disclosures Clinical trials and studies funded by EDCTP,
More informationTreatment of XDR-TB. Focus on the Nix-TB and ZeNix Trials. RESIST-TB Webinar 11 January 2018 Daniel Everitt, MD
Treatment of XDR-TB Focus on the Nix-TB and ZeNix Trials RESIST-TB Webinar 11 January 2018 Daniel Everitt, MD Global Alliance for TB Drug Development Outline of Discussion TB Alliance Approach to Treatment
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationUpcoming TB Alliance Studies. CPRT DST Review September, 2014
Upcoming TB Alliance Studies CPRT DST Review September, 2014 STAND PaMZ Ph 3 STAND: Phase 3 Trial of the Pa-M-Z Regimen Participants with newly diagnosed smear positive DS- and MDR-TB DS Pa(100mg)-M-Z
More informationNew TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention New TB Medications Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationA Review of the Sutezolid (PNU ) Patent Landscape
2014 A Review of the Sutezolid (PNU-100480) Patent Landscape A scoping report JANUARY 2014 A Review of the Sutezolid (PNU-100480) Patent Landscape UNITAID Secretariat World Health Organization Avenue Appia
More informationActivity of PNU and its major metabolite in whole blood and broth culture models of TB
Activity of PNU 100480 and its major metabolite in whole blood and broth culture models of TB Paul Converse 1, Jin Lee 1, Kathy Williams 1, Opokua Amoabeng 1, Kim Dionne 1, Nicole Parish 1, Robert Wallis
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationProblems, progress and evaluation of agents in clinical development ACCEPTED. Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
AAC Accepts, published online ahead of print on 15 December 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00749-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationMultidrug-resistant tuberculosis in children
Multidrug-resistant tuberculosis in children James Seddon Clinical Lecturer Imperial College London UCL-TB and LSHTM TB Centre World TB Day 2015 24th March 2015 Outline Burden Recent studies Preventive
More informationImproving Translation in TB Drug Development Through Quantitative Modeling. CPTR Workshop 2016, Washington DC
Improving Translation in TB Drug Development Through Quantitative Modeling Lessons from Recent Phase III TB Trials CPTR Workshop 2016, Washington DC Christian Lienhardt Global TB Programme WHO, Geneva,
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationNIAID TB Therapeutic Clinical Research Priorities. Prognostic biomarkers for disease progression, treatment response/relapse
NIAID TB Therapeutic Clinical Research Priorities New drugs and combinations for DS and DR TB: Efficient Phase I and II evaluations Phase III Killing Persisters Sterilizing activity is crucial Prognostic
More informationPAEDIATRIC TB TRIAL UPDATE
PAEDIATRIC TB TRIAL UPDATE ANNEKE C. HESSELING PROFESSOR IN PAEDIATRICS AND CHILD HEALTH DIRECTOR: DESMOND TUTU TB CENTRE DEPARTMENT OF PAEDIATRICS AND CHILD HEALTH STELLENBOSCH UNIVERSITY, SOUTH AFRICA
More informationClinical Trials Lecture 4: Data analysis
Clinical Trials Lecture 4: Data analysis Dick Menzies, MD Respiratory Epidemiology and Clinical Research Unit Montreal Chest Institute TB Research methods course July 17, 2014 Lecture 4: Data analysis
More informationIssues in TB Drug Development for Sensitive Disease - Clinical Development
Issues in TB Drug Development for Sensitive Disease - Clinical Development GATB Open Forum New Delhi, 5-6 May 2008 Christian Lienhardt, MD, DTM, MSc, PhD IRD, Paris, France & International Union Against
More informationOverview: TB Alliance Drug Development Pipeline
Overview: TB Alliance Drug Development Pipeline Mengchun Li, MD Head of Pharmacovigilance, TB Alliance Mar 26, 2018 TB Alliance is a not for profit organization dedicated to the discovery and development
More informationTB Updates for the Physician Rochester, Minnesota June 19, 2009
TB Updates for the Physician Rochester, Minnesota June 19, 2009 Recent Findings & Activities of the Tuberculosis Trials Consortium (TBTC) Bill Burman Denver TBTC Unit & Denver Public Health Recent findings
More informationHA Convention 2016 : Special Topic Session 3 May 2016
HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis
More informationCurrent Status in the Development of the New Anti-Tuberculosis Drugs
National Scientific Meeting TB UPDATE IX 2017 WORKSHOP AND SYMPOSIUM Novel Management to End TB Hotel Bumi Surabaya 29-30 April 2017 Current Status in the Development of the New Anti-Tuberculosis Drugs
More informationThe clinical pharmacology and drug interactions of bedaquiline
7 TH FIDSSA 2017 The clinical pharmacology and drug interactions of bedaquiline Helen McIlleron Division of Clinical Pharmacology University of Cape Town 20 years 2 drugs conditional approval based on
More informationDrug Interactions with ART and New TB drugs: What Do We Know?
Drug Interactions with ART and New TB drugs: What Do We Know? HIV/TB Research Frontiers Meeting 20 th Conference on Retroviruses and Opportunistic Infections 3 March 2013 Presented by: Kelly Dooley MD,
More informationPhase III Clinical Trial Results at the 48 th Union World Conference on Lung Health: Implications for the Field 1
Phase III Clinical Trial Results at the 48 th Union World Conference on Lung Health: Implications for the Field 1 Preliminary results from two phase III drug-resistant TB (DR-TB) clinical trials were presented
More informationTreatment of Tuberculosis. Dr Sarabjit Chadha The Union
Treatment of Tuberculosis Dr Sarabjit Chadha The Union History of treatment of TB. Believed to be as old as mankind Spinal TB has been diagnosed in Egyptian mummies dating 2400 BC Egyptian medical treatise
More informationThe shorter regimen for MDR-TB: evidence and pitfalls
The shorter regimen for MDR-TB: evidence and pitfalls Helen Cox 10 November 2017 What is the shortened regimen? Current conventional regimen (SA): Intensive Phase (at least 6 months): PZA / (EMB) / Kana
More informationNewer anti-tb drugs and regimens. DM Seminar
Newer anti-tb drugs and regimens DM Seminar 31-10-14 Why are newer drugs/regimens needed? Problems with current drugs/regimens Drug resistance Drug interaction of anti-tubercular drugs with ART Long duration
More informationNew Drugs, New Treatments, Shorter Regimens
New Drugs, New Treatments, Shorter Regimens Sarah K. Brode, MD MPH FRCP(C) West Park Healthcare Centre, University Health Network, University of Toronto TB Elimination: Back to Basics November 16, 2016
More informationNon-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More informationSoedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital MDR-TB is a public health crisis 480 000 people developed MDR-TB in
More informationThe treatment of patients with initial isoniazid resistance
The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background
More informationTherapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB?
Therapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB? Mark Hatherill South African Tuberculosis Vaccine Initiative (SATVI) University of Cape Town, South Africa 1 1. The need for a therapeutic
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationSoedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital There were an estimated 10.4 million new TB cases in 2015, higher than
More informationPerspectives for new treatments for MDR-TB
Perspectives for new treatments for MDR-TB Life cycle of M. tuberculosis Active TB in 2015 10.4 million cases >1.4 million deaths Latent TB >2 billion cases Switzerland 564 cases (18 MDR) 2 Koul et al.
More informationMultidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017
Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationCertainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f
Author(s): STREAM Stage 1 Trial investigators reported for the Guideline Development Group for the WHO treatment guidelines on MDR/RR-TB, 2018 update (6 July 2018) - FINAL RESULTS Question: PICO 1. In
More informationAuthors Schluger, N; Karunakara, U; Lienhardt, C; Nyirenda, T E; Chaisson, R
MSF Field Research Building clinical trials capacity for tuberculosis drugs in highburden countries Item type Article Authors Schluger, N; Karunakara, U; Lienhardt, C; Nyirenda, T E; Chaisson, R Citation
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationFinal Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR)
Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR) Tuberculosis (TB). AH Diacon*, A Pym**, MP Grobusch, G. Churchyard, T De
More informationWhat is the recommended shorter treatment regimen for MDR-TB?
DRTB STAT + TAG BRIEF Is shorter better? Is shorter better? Understanding the shorter regimen for treating drugresistant tuberculosis by Safiqa Khimani Edited by Vivian Cox, Mike Frick, Jennifer Furin,
More informationNIAID TB/HIV Clinical Research Coordination and Collaborations and Global Activities NOVEMBER, 2011
NIAID TB/HIV Clinical Research Coordination and Collaborations and Global Activities NOVEMBER, 2011 Map of China 2 27 Institutes and Centers NIAID 5 Science Divisions Clinical Research DCR Microbiology
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationChapter 5 Treatment. 5.1 First-Line Antituberculous Treatment
Chapter 5 Treatment Abstract In this chapter the treatment of drug sensitive and drug resistant TB and timing of antiretroviral treatment for HIV infected patients will be reviewed. Emphasis is placed
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationTB Prevention in PLHIV: Options Other Than Isoniazid. Johns Hopkins Center for Tuberculosis. Research. Richard E. Chaisson, MD
TB Prevention in PLHIV: Options Other Than Isoniazid Johns Hopkins Center for Tuberculosis Richard E. Chaisson, MD Research Johns Hopkins University Center for Tuberculosis Research Consortium to Respond
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 5, Issue 2 Newsletter Date: February 2013 APSR EDUCATION PUBLICATION Inside this issue: Tuberculosis Multidrug-resistant pulmonary tuberculosis treatment regimens and patient
More informationTBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
More informationStatus of the TB Drug Pipeline: Clinical Candidates
Status of the TB Drug Pipeline: Clinical Candidates Ann M. Ginsberg, MD, PhD Global Alliance for TB Drug Development Open Forum III Delhi, India Global TB Drug Portfolio: 7 clinical candidates gatifloxacin
More informationBEDAQUILINE (Sirturo)
An Activist s Guide to tag@treatmentactiongroup.org www.treatmentactiongroup.org BEDAQUILINE (Sirturo) By Erica Lessem and Lindsay McKenna February 2013 I. Introduction New drugs are urgently needed to
More informationResearch Excellence to Stop TB Resistance. Plan for MDR-TB Clinical Trials: An Overview March 9, 2010
RESIST-TB: Summary Research Excellence to Stop TB Resistance Plan for MDR-TB Clinical Trials: An Overview March 9, 2010 The current epidemic of Multidrug-Resistant Tuberculosis (MDR-TB) is a major threat
More informationManagement of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building
Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention
More informationWhat He Said: Rifampin versus Rifapentine
What He Said: Rifampin versus Rifapentine Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis.
More informationNew Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
SUPPLEMENT ARTICLE New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future Christian Lienhardt, 1,2 Mario Raviglione, 2 Mel Spigelman, 3 Richard Hafner, 4
More informationTB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB
TB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB Rada Savic, PhD Medical Consultant Meeting San Antonio, TX November 29-30, 2018 1 EXCELLENCE EXPERTISE
More informationTuberculosis Epidemiology
Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline
More informationTB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS
TB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS ANNEKE C. HESSELING RESIST TB WEBINAR 20 APRIL 2017 DESMOND TUTU TB CENTRE PROFESSOR IN PAEDIATRICS AND CHILD
More informationSummary of the risk management plan (RMP) for Sirturo (bedaquiline)
EMA/16634/2014 Summary of the risk management plan (RMP) for Sirturo (bedaquiline) This is a summary of the risk management plan (RMP) for Sirturo, which details the measures to be taken in order to ensure
More informationSterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2011, p. 5485 5492 Vol. 55, No. 12 0066-4804/11/$12.00 doi:10.1128/aac.05293-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Sterilizing
More informationTuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control
Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control Suvanand Sahu Deputy Executive Director Stop TB Partnership Secretariat Tuberculosis TB epidemic is declining very slowly We
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationNew Frontiers: Innovation and Access
8 th Regional TB Symposium - Tashkent, Uzbekistan New Frontiers: Innovation and Access New Guidelines: An Opportunity for National Programmes and Patients: Evidence for new WHO recommendations on MDR-TB
More informationBetter Diagnostics for Tuberculosis: A Bolder Vision for TB Control. Peter M. Small, MD Senior Program Officer
Better Diagnostics for Tuberculosis: A Bolder Vision for TB Control Peter M. Small, MD Senior Program Officer peter.small@gatesfoundation.org June 21, 2010 Disclosure No financial/industry conflicts Patent
More informationWhat is drug resistance? Musings of a clinician
What is drug resistance? Musings of a clinician William Burman MD Denver Public Health Tuberculosis Trials Consortium Financial disclosures Tibotec (developer of TMC207 and several antiretroviral drugs)
More informationACCESS TO MEDICINES. Update on tuberculosis field activities
ACCESS TO MEDICINES Update on tuberculosis field activities Update on clinical activities 1/3 Latent TB Prevent study (S26) main study (8053 patients) PK substudy construction of a POPPK model Paediatric
More informationWhat Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ
What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ Outline Combination prevention for HIV Approaches to TB prevention Individual Household/key
More informationEnfermedades Infecciosas y Microbiología Clínica
Volumen 29, Extraordinario 1, Marzo 2011 Publicación mensual www.elsevier.es/eimc PUBLICACIÓN OFICIAL DE LA SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA Update on tuberculosis
More informationPrinciples and practice of treating drug-sensitive TB
Principles and practice of treating drug-sensitive TB Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationScreening and management of latent TB Infection Gerry Davies
Screening and management of latent TB Infection Gerry Davies Reader in Infection Pharmacology Institutes of Infection and Global Health & Translational Medicine HIV Scientific Meeting Liverpool 21st July
More informationAnti-Infective Drugs Advisory Committee Meeting. Briefing Document. TMC207 (bedaquiline) Treatment of Patients with MDR-TB NDA
ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE 1 Anti-Infective Drugs Advisory Committee Meeting Briefing Document TMC207 (bedaquiline) Treatment of Patients with MDR-TB NDA 204-384
More informationCompassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India
AGORA RESEARCH LETTER Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India To the Editor: Bedaquiline, a mycobacterial ATP synthase inhibitor [1], is the first
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationMONITORING COMPASSIONATE USE OF NEW DRUGS FOR TUBERCULOSIS
MONITORING COMPASSIONATE USE OF NEW DRUGS FOR TUBERCULOSIS MONITORING COMPASSIONATE USE OF NEW DRUGS FOR TUBERCULOSIS Compassionate Use (CU) programs have been utilized for new cancer and HIV drugs to
More informationTuberculosis Medicines
2013 Tuberculosis Medicines Technology and Market Landscape SEPTEMBER 2013 2013 Tuberculosis Medicines Technology and Market Landscape UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationSurgery for MDR/XDR Tuberculosis
Surgery for MDR/XDR Tuberculosis John D. Mitchell, M.D. Davis Endowed Chair in Thoracic Surgery Professor and Chief, General Thoracic Surgery Department of Surgery University of Colorado School of Medicine
More informationUsing delamanid in MDR-TB Francis Varaine MSF
Using delamanid in MDR-TB Francis Varaine MSF Symposium on new treatment and approaches to Tuberculosis Yerevan TB February 2015 A new anti-tb drug Nitro-dihydro-imidazo-oxazole derivative Mechanism of
More informationProcurement update: StopTB Partnership - Global Drug Facility (GDF)
Procurement update: StopTB Partnership - Global Drug Facility (GDF) Magali BABALEY Strategic Procurement and Business Intelligence Manager Stop TB Partnership, Global Drug Facility (GDF) team joint UNICEF-UNFPA-WHO
More informationHistoric Perspective on HIV and TB Research in Pregnant Women
Historic Perspective on HIV and TB Research in Pregnant Women Lynne M. Mofenson, M.D. Senior HIV Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation High Burden of TB/HIV in Women - 2016 TB HIV
More informationHIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationHigh-dose rifampin: potential for treatment shortening
High-dose rifampin: potential for treatment shortening Martin Boeree, MD, PhD Associate Professor Radboud University Nijmegen Medical Centre Rob Aarnoutse, Georgette Plemper van Balen, Andreas Diacon,
More informationTuberculosis: update 2013
Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference
More informationDiscovery & Development: Bedaquiline For Drug Resistant Tuberculosis. Wim Parys, MD Head R&D J&J Global Public Health
Discovery & Development: Bedaquiline For Drug Resistant Tuberculosis Wim Parys, MD Head R&D J&J Global Public Health - 500.000 Y (Turkey): TB infection suggestive bone lesions - 9000 Y (Alit-Yam, Israel)
More informationGuidelines for treatment of drug-susceptible tuberculosis and patient care
TREATMENT OF TUBERCULOSIS Guidelines for treatment of drug-susceptible tuberculosis and patient care 2017 UPDATE Annex 4 EVIDENCE-TO-DECISION TABLES TREATMENT OF TUBERCULOSIS Guidelines for treatment
More informationRoll-out of new TB drugs and short-course regimens in the Kyrgyz Republic
Treating Patient, Not Disease: People-Centered Approach 1-2 March, 2018, BISHKEK, KYRGYZSTAN Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic A. Kadyrov, PhD in Medicine Director
More informationMEDICINES CATALOG NOVEMBER 2018 GLOBAL DRUG FACILITY (GDF)
NOVEMBER 2018 MEDICINES CATALOG GLOBAL DRUG FACILITY (GDF) Ensuring an uninterrupted supply of quality-assured, affordable tuberculosis (TB) medicines and diagnostics to the world. stoptb.org/gdf Stop
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationPreventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical
More informationQuestions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs
Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes
More informationPharmacokinetics and doses of antituberculosis drugs in children
Pharmacokinetics and doses of antituberculosis drugs in children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Declarations I have no conflict of interest
More informationOur experience on other diseases
Global supply chain for MDR TB drugs Our experience on other diseases Dr Robert Sebbag 31 st July 2012 ACCESS TO MEDICINES 1 Second-line drugs for MDR TB Definition: resistance to (at least) R and H, the
More information"Sterilization of TB disease in
11/1/1 "Sterilization of TB disease in mice " Jacques Grosset Pharmacodynamics of daily rifapentine and rifampin in mice Free rifam mycin Concentrati ion/mic 1 1 Rifapentine (1mg/kg) Free rifam mycin Concentrati
More information